Celon Pharma S.A. (WSE:CLN)

Market Cap	1.01B -16.2%
Revenue (ttm)	257.64M +24.9%
Net Income	106.81M
EPS	2.04
Shares Out	53.86M
PE Ratio	9.18
Forward PE	27.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,819
Open	18.96
Previous Close	19.00
Day's Range	18.54 - 19.18
52-Week Range	18.00 - 23.50
Beta	0.62
Analysts	Sell
Price Target	20.38 (+8.75%)
Earnings Date	Nov 18, 2026

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 560
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CLN

Financial Performance

In 2025, Celon Pharma's revenue was 242.21 million, an increase of 17.83% compared to the previous year's 205.55 million. Losses were -79.36 million, 130.4% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for CLN stock is "Sell." The 12-month stock price target is zł 20.38, which is an increase of 8.75% from the latest price.

Price Target

zł 20.38

(8.75% upside)

Analyst Consensus: Sell

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 26, 2026

Data Sources Report a data error